|
|
|
|
||
I wonder how much we're worth...... given that ARQL and Synthorx traded for ~$2.5B a piece. I would hope Enyedy is keeping his cool and continuing to look for a partnership on favorable terms. Immunogen's IP is world class, and this would be more fair to shareholders who want a share of the trailing cash flows. |
return to message board, top of board |